Proteina | Identity (NSC) | DH5α (MIC) | MDREC (MIC) | MRSA (MIC) | VREF (MIC) | HCT-116 (IC-50) |
---|
DHFR | 309401 | 7.813 | 125 | 31.25 | 31.25 | 0.130 |
740* | ND | ND | ND | 500 | 0.048 |
339578* | 62.5 | 250 | 31.25 | 31.25 | 6.11 |
382035* | ND | ND | 31.25 | 31.25 | 0.182 |
754230* | ND | ND | ND | ND | <<0.031 |
1000001 | 111552 | NA | NA | NA | NA | 2.2 |
246131@ | NA | NA | NA | NA | 0.024 |
30205 | NA | NA | NA | NA | 0.146 |
88882 | NA | NA | N A | NA | 4.44 |
 | 106863 | NA | NA | NA | NA | 14.5 |
1000006 | 92794 | NA | NA | NA | NA | 9.78 |
TrpRS | 750690Â¥ | NA | NA | NA | NA | 1.11 |
88882 | NA | NA | NA | NA | 4.44 |
37168 | NA | NA | NA | NA | 1.34 |
- *Reported inhibitors of DHFR independently picked up by our predictions and validated experimentally. @Small molecule with known anti-cancer properties (valrubicin). ¥Small molecules with known anticancer properties (Sunitinib), MIC: Minimum inhibitory concentration required for 90% clearance, μg/mL units. ND: No significant inhibition. NA: not applicable. DH5α: E. coli strain DH5α, MRSA: Methicillin-resistant S. aureus, MDREC: Multi-drug resistant E. coli, VREF: Vancomycin-resistant E. faecium, HCT-116: Colon carcinoma cell line. IC-50: inhibitory concentration for 50% growth inhibition, μg/mL units. aFor additional details, see legend from Table 1. bThe values reported in this table are experimental in-vitro values.